BEDMINSTER, N.J., Dec. 2, 2024 /PRNewswire/ -- Biocodex, a global pharmaceutical company and long-time pioneer in the treatment of rare pediatric diseases, will present seven studies at the upcoming AES 2024 Annual Meeting in Los Angeles, CA, from December 6-10. The studies focus on the use of stiripentol and its impact on patients with Dravet syndrome.
Carla Schad, M.D., Biocodex North American Medical Officer, previewed what providers can expect to see from Biocodex at AES this year.
“Biocodex USA is thrilled to be attending AES this year. We are dedicated to bringing new data to our health care providers and researchers; but most importantly, our AES attendance will highlight our partnerships with Thought Leaders and Advocates. At Biocodex, our commitment and promise are to always keep the patient first.”
Key scientific and patient-focused data include:
Poster Number | Title of Poster | Poster on Display | Author Present Time |
1.145
| Best Practice Communication during the First Diagnosis Consultations with Caregiver of Young Children with Dravet Syndrome: An International Delphi Consensus | 12:00 PM – 6:00 PM Session 1, Saturday December 7, South Hall H, Level 1
| 12:00 PM -2:00 PM |
1.413
| Efficacy of Stiripentol Beyond Generalized Tonic-Clonic Seizures: A Retrospective Analysis of DRAVET and Non-Dravet Patient Records | 12:00 PM – 6:00 PM Session 1, Saturday December 7, South Hall H, Level 1 | 12:00 PM -2:00 PM |
1.414
| Therapeutic Maintenance of Stiripentol in Dravet Syndrome: A Comprehensive Literature Analysis | 12:00 PM – 6:00 PM Session 1, Saturday December 7, South Hall H, Level 1 | 12:00 PM -2:00 PM |
1.491
| Real World Utilization of Stiripentol by United States Prescribers: A Holistic Approach to Dosing | 12:00 PM – 6:00 PM Session 1, Saturday December 7, South Hall H, Level 1 | 12:00 PM -2:00 PM |
3.406
| Results of the DIAVEY study: a European post-marketing safety survey on stiripentol use | 8:00 AM – 2:00 PM Session 3, Monday December 9, South Hall H, Level 1 | 12:00 PM – 1:45 PM |
3.416
| Results of a Long-Term Post-Marketing Surveillance Study on Stiripentol Safety and Efficacy in a Large Cohort of Japanese Patients | 8:00 AM – 2:00 PM Session 3, Monday December 9, South Hall H, Level 1 | 12:00 PM – 1:45 PM |
3.417
| Stiripentol use in Dravet patients in the USA | 8:00 AM – 2:00 PM Session 3, Monday December 9, South Hall H, Level 1 | 12:00 PM – 1:45 PM |
Symposia & CME Programs at the AES 2024 Annual Meeting
Biocodex will be hosting two informational symposia at this conference focusing on the following:
Symposia Title | Description | Speaker | Time, Location |
Communicating a Diagnosis of Dravet Syndrome (DS) to Parents/Caregivers: An International Delphi consensus
| An informative program surveying the best practices in communicating a Dravet Syndrome (DS) diagnosis to parents/caregivers from the international Delphi consensus. This program will help practitioners facilitate a more structured diagnostic consultation and offer further support to parents at the time of diagnosis. | Katherine Nickels, MD | 4:30 PM – 5:30 PM Saturday, December 7 Los Angeles Convention Center, Exhibition Hall |
Optimizing a Treatment Option for Patients With Dravet Syndrome
| An informative presentation that discusses the impact of Dravet syndrome, signs and symptoms of the disease, as well as the importance of early intervention. Learn about an approved therapy for patients with Dravet syndrome. | James W. Wheless, BScPharm, MD, FAAP, FACP, FAAN, FAES
| 10:15 AM – 11:15 AM Sunday, December 8 Los Angeles Convention Center, Exhibition Hall |
Biocodex is also sponsoring a CME program on Saturday, December 7, 6:00 PM – 9:00 PM in the JW Marriot, Los Angeles California titled, “Mortality Risk with Dravet Syndrome: Let’s Check That Box.” This program will explore the importance of the following in Dravet syndrome: early diagnosis, risk factors for increased mortality, ways to improve communication with caregivers about increased mortality risk and evaluating the impact of targeted therapies on mortality risk.
About Dravet Syndrome
Dravet syndrome is a rare and severe genetic epilepsy that most commonly begins before the age of one when an otherwise normally developing child begins having frequent, prolonged seizures.1 These seizures can cause lasting damage, which over time can lead to developmental and cognitive delays, affecting coordination, language, and behavior.2 Its incidence is estimated to be 1 in 16,000 births.3
About Biocodex
Founded in 1953, Biocodex is a French family-owned pharmaceutical company that leverages life sciences, placing health and its balance at the heart of its corporate initiatives, innovations, and development for the benefit of patients worldwide.
A pioneer and leader in human microbiota health by marketing the first probiotic strain, the global organization has developed its activities around three strategic areas: microbiota, women’s health, and orphan diseases. It has also expanded its expertise by investing in other health areas, such as pain management, respiratory and ENT pathways, and neurology.
Present in 115 countries through its subsidiaries and partners, Biocodex emphasizes its territorial roots, which are central to its corporate social responsibility, producing in France for over 50 years across most of its value chain.
The Biocodex global organization is comprised of 1,700 employees who share common values, embodied in their daily missions and rooted in the company’s DNA.
To learn more about Biocodex visit: www.biocodex.us/en/
To learn more about DIACOMIT visit: www.diacomit.com
INDICATION
DIACOMIT (stiripentol) is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more. There are no clinical data to support the use of DIACOMIT as monotherapy in Dravet syndrome.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
None
WARNINGS & PRECAUTIONS
Somnolence
DIACOMIT can cause somnolence. Monitor patients for somnolence, particularly when DIACOMIT is used concomitantly with other CNS depressants or clobazam, which is also known to cause somnolence.
Decreased Appetite and Decreased Weight
DIACOMIT can cause decreases in appetite and weight. The growth and weight of pediatric patients treated with DIACOMIT should be carefully monitored.
Neutropenia and Thrombocytopenia
DIACOMIT can cause significant declines in neutrophil and platelet counts. Hematologic testing should be obtained prior to starting treatment with DIACOMIT and then every 6 months.
Withdrawal Symptoms
As with most antiepileptic drugs (AEDs), DIACOMIT should be gradually withdrawn to minimize the risk of increased seizure frequency and status epilepticus.
Risks in Patients with Phenylketonuria (PKU)
DIACOMIT for oral suspension contains phenylalanine, which can be harmful to patients with PKU. Before prescribing DIACOMIT for oral suspension to a patient with PKU, consider the total daily intake of phenylalanine from all sources, including DIACOMIT for oral suspension. DIACOMIT capsules do not contain phenylalanine.
Suicidal Behavior and Ideation
AEDs, including DIACOMIT, increase the risk of suicidal thoughts or behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
ADVERSE REACTIONS
The most common adverse reactions that occurred in at least 10% of DIACOMIT-treated patients and more frequently than on placebo were somnolence, decreased appetite, agitation, ataxia, decreased weight, hypotonia, nausea, tremor, dysarthria, and insomnia.
PREGNANCY
There are no adequate data on the developmental risks associated with the use of DIACOMIT in pregnant women. Based on animal data, DIACOMIT may cause fetal harm.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AEDs, such as DIACOMIT, during pregnancy. Physicians are advised to recommend that pregnant patients taking DIACOMIT enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry (information at www.aedpregnancyregistry.org). This can be done by calling the toll-free number 1‑888‑233-2334 and must be done by patients themselves or their caregiver. To report suspected adverse reactions, contact Biocodex at 1‑866‑330-3050 or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.
Please see full DIACOMIT Prescribing Information at www.DIACOMIT.com.
References: 1. Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52 Suppl 2:3-9.doi:10.1111/j.1528-1167.2011.02994. 2. Genton P, Velizarova R, Dravet C. Dravet syndrome: the long-term outcome. Epilepsia. 2011;52 Suppl 2:44-49. doi:10.1111/j.1528-1167.2011.03001. 3. Wu YW, Sullivan J, McDaniel SS, et al. Incidence of Dravet Syndrome in a US Population. Pediatrics. 2015;136(5):e1310-e1315. doi:10.1542/peds.2015-1807
© 2024 Biocodex, Inc. All rights reserved. DIACOMIT® is a registered trademark of Biocodex, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/biocodex-to-present-new-data-at-the-american-epilepsy-society-aes-2024-annual-meeting-302319863.html
SOURCE Biocodex, Inc.
